ACG, the world’s most integrated provider of solid-dosage and packaging solutions, announces the launch of DryPod™, a next-generation, desiccant-based, cold-form laminate engineered to protect highly moisture-sensitive drug molecules. DryPod™ marks a major advancement for pharmaceutical manufacturers who have long grappled with limited availability, rigid technologies, and compatibility issues within existing desiccant cold-form solutions.
Moisture protection is essential to ensure drug potency throughout the product’s retail life. However, current market offerings rely heavily on a single patented co-extrusion-based technology, creating challenges such as restricted machine compatibility, dependence on specific lidding foils, long lead times, limited supplier options, and inconsistent on-ground technical support. DryPod™ overcomes these barriers, giving pharmaceutical companies the freedom to innovate without compromising product protection, regulatory compliance, or operational efficiency.
Unlike legacy co-extruded structures, DryPod™ is built using a proprietary lamination-based approach, enabling consistent performance across all standard blister-forming technologies. This eliminates the need for specialized retrofits or process changes and gives manufacturers complete flexibility to run DryPod™ on their existing blister lines. The laminate can also be sealed with any PE-sealable lidding foil, reducing procurement dependencies and ensuring supply-chain agility across global operations.
A significant differentiator for DryPod™ is its patent-clean design. Engineered with zero overlap with existing active patents in the desiccant co-extrusion space, DryPod™ offers pharmaceutical companies complete legal clarity and peace of mind when switching suppliers, scaling production, or expanding into new markets. This removes a longstanding barrier for companies seeking secure, long-term, and globally compliant moisture-protection solutions.
DryPod™ is supported by ACG’s extensive global technical service network, ensuring smooth onboarding, rapid troubleshooting, and optimized packaging performance across diverse manufacturing environments. With its advanced protection capabilities and universal compatibility, DryPod™ represents a future-ready solution for safeguarding highly moisture-sensitive molecules.
“DryPod™ is built for the realities of modern pharmaceutical manufacturing,” said Dr. Akbar Ali, General Manager and Head of Development and Technologies at ACG. “Manufacturers working with moisture-sensitive molecules have faced years of constraints due to rigid technologies and supply limitations. DryPod™ directly addresses these challenges, empowering innovators to bring critical therapies to market more efficiently and reliably.”
DryPod™ is now commercially available worldwide.
